Jennifer Scott
Psychiatric/Mental Health · Terre Haute, INNPI 1215552898
Payments from drug & device makers
Across 694 payments — averaging $14.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Lundbeck LLC$1K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$892
- Teva Pharmaceuticals USA, Inc.$822
- Vanda Pharmaceuticals Inc.$683
- plus $5K from 27 others
What the payments were for
- Food & beverage$10,15799%
- Education$1171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 89 | $1,149 |
| Lundbeck LLC | 63 | $1,124 |
| AbbVie | 91 | $1,049 |
| Otsuka America Pharmaceutical, Inc. | 58 | $892 |
| Teva Pharmaceuticals USA, Inc. | 49 | $822 |
| Vanda Pharmaceuticals Inc. | 36 | $683 |
| Neurocrine Biosciences, Inc. | 36 | $659 |
| Alkermes, Inc. | 31 | $512 |
| Johnson & Johnson | 38 | $429 |
| Supernus Pharmaceuticals, Inc. | 54 | $398 |
| Corium, LLC | 24 | $366 |
| Indivior Inc. | 23 | $351 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $299 |
| Axsome Therapeutics, Inc. | 12 | $273 |
| Ironshore Pharmaceuticals Inc. | 13 | $194 |
| Collegium Pharmaceutical, Inc. | 12 | $143 |
| Sunovion Pharmaceuticals Inc. | 8 | $138 |
| Tris Pharma Inc | 7 | $125 |
| E.r. Squibb & Sons, L.L.C. | 5 | $108 |
| Idorsia Pharmaceuticals US Inc | 5 | $100 |
| Avanir Pharmaceuticals, Inc. | 6 | $98 |
| Noven Therapeutics, LLC | 3 | $57 |
| Eisai Inc. | 3 | $46 |
| Almatica Pharma LLC | 2 | $41 |
| OWP Pharmaceuticals, Inc. | 2 | $39 |
| Novartis | 2 | $36 |
| Amgen | 2 | $30 |
| Neuronetics, Inc. | 1 | $29 |
| Tempus AI, Inc | 1 | $22 |
| Luye Pharma (USA) Ltd. | 1 | $19 |
| Neos Therapeutics, LP | 1 | $18 |
| GSK | 1 | $14 |
| Brainsway USA Inc | 1 | $11 |
How this compares
$10,273 in reported general payments places this provider in the 95th percentile of 729 psychiatric/mental health providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 27 | $233,989 |
| Austedo XrDeutetrabenazine | 11 | $85,086 |
| FanaptIloperidone | 39 | $68,994 |
| CaplytaLumateperone Tosylate | 41 | $68,903 |
| VraylarCariprazine Hcl | 22 | $29,849 |
| LybalviOlanzapine/Samidorphan Malate | 17 | $26,077 |
| RexultiBrexpiprazole | 12 | $17,375 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $12,160 |
| Clozapine | 171 | $12,143 |
| Aripiprazole | 69 | $5,041 |
| Olanzapine | 78 | $4,107 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,079 |
| Lurasidone Hcl | 32 | $3,773 |
| Guanfacine Hcl ErGuanfacine Hcl | 63 | $3,562 |
| Perphenazine | 34 | $3,230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $659 | $233,98927 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $822 | $85,08611 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $683 | $68,99439 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,149 | $68,90341 claims |
| AbbVieVraylar | $1,049 | $29,84922 claims |
| Alkermes, Inc.Lybalvi | $512 | $26,07717 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $892 | $17,37512 claims |
| Axsome Therapeutics, Inc.Auvelity | $273 | $12,16011 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $299 | $4,07912 claims |
| Almatica Pharma LLCSertraline Hcl | $41 | $625139 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Terre Haute
- Brooke KempfTerre Haute$1.1M
- Lisa ReinhardtTerre Haute$7K
- Margaret BrumfieldTerre Haute$5K
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Trina GreenwaldMarion$107K
- Paul DuncanJeffersonville$46K
- Morgan StamperConnersville$42K
- Jennifer JimenezUnion Mills$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.